Harpoon Therapeutics Inc
NASDAQ:HARP
Harpoon Therapeutics Inc
NASDAQ:HARP
Price:
23.01 USD
Market Closed
Updated:
May 3, 2024
Section:
Relative Value
The Relative Value of one
HARP
stock under the Base Case scenario is
11.24
USD.
Compared to the current market price of 23.01 USD,
Harpoon Therapeutics Inc
is
Overvalued by 51%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
HARP
Relative Value
Base Case
11.24
USD
Overvaluation 51%
Valuation Multiples
Multiples Across Competitors
HARP Competitors Multiples
Harpoon Therapeutics Inc Competitors
Harpoon Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Harpoon Therapeutics Inc
NASDAQ:HARP
|
492.3m USD | 13.2 | -16.1 | -13.2 | -12.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
284B USD | 5.2 | 58.9 | 12.8 | 19.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
149.1B USD | 5.3 | 22.2 | 16.5 | 24.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.1B USD | 10.4 | 28.5 | 22.8 | 23.9 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
102.6B USD | 7.8 | 25.9 | 17.4 | 19.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133B AUD | 6.2 | 35.4 | 21.4 | 26.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.4B USD | 3 | 168.2 | 6.7 | 8.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
48B USD | 7 | -10.2 | -11 | -9.4 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.1B USD | 3.2 | 26.6 | 13.7 | 17.1 | |
| KR |
|
Celltrion Inc
KRX:068270
|
38.9T KRW | 17.9 | 72.5 | 44.4 | 61.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
